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Abstract
Lung CD4+ T cells accumulate as chronic obstructive pulmonary disease (COPD) progresses, but their role in pathogenesis
remains controversial. To address this controversy, we studied lung tissue from 53 subjects undergoing clinically-indicated
resections, lung volume reduction, or transplant. Viable single-cell suspensions were analyzed by flow cytometry or
underwent CD4+ T cell isolation, followed either by stimulation with anti-CD3 and cytokine/chemokine measurement, or by
real-time PCR analysis. In lung CD4+ T cells of most COPD subjects, relative to lung CD4+ T cells in smokers with normal
spirometry: (a) stimulation induced minimal IFN-c or other inflammatory mediators, but many subjects produced more
CCL2; (b) the T effector memory subset was less uniformly predominant, without correlation with decreased IFN-c
production. Analysis of unstimulated lung CD4+ T cells of all subjects identified a molecular phenotype, mainly in COPD,
characterized by markedly reduced mRNA transcripts for the transcription factors controlling TH1, TH2, TH17 and FOXP3+ T
regulatory subsets and their signature cytokines. This mRNA-defined CD4+ T cell phenotype did not result from global
inability to elaborate mRNA; increased transcripts for inhibitory CD28 family members or markers of anergy; or reduced
telomerase length. As a group, these subjects had significantly worse spirometry, but not DLCO, relative to subjects whose
lung CD4+ T cells expressed a variety of transcripts. Analysis of mRNA transcripts of unstimulated lung CD4+ T cell among all
subjects identified two distinct molecular correlates of classical COPD clinical phenotypes: basal IL-10 transcripts correlated
independently and inversely with emphysema extent (but not spirometry); by contrast, unstimulated IFN-c transcripts
correlated independently and inversely with reduced spirometry (but not reduced DLCO or emphysema extent). Aberrant
lung CD4+ T cells polarization appears to be common in advanced COPD, but also exists in some smokers with normal
spirometry, and may contribute to development and progression of specific COPD phenotypes.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a growing
cause of worldwide death and disability [1]. COPD is an
inflammatory condition [2] triggered by inhaled oxidative stress,
most commonly from cigarette smoking or indoor air pollution [3].
COPD is characterized by airflow limitation resulting from
alveolar destruction plus airway changes (including loss of
elasticity, wall thickening and increased mucus production). Once
initiated, this airflow limitation is incompletely reversible and
progressive despite removal of the inciting stress, as by smoking
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e96421cessation [4]. Because no current medications halt COPD
progression or alter mortality, improved understanding of its
pathogenesis is crucial.
As COPD progresses, multiple leukocyte types accumulate in
the lungs [5]. Best studied have been lung CD8+ T cells, which
increase production of IFN-c [6–8] and cytotoxic molecule
expression [9] in direct correlation with spirometrically-defined
COPD severity. Lung CD4+ T cells have been less well-explored,
although their numbers also steadily increase [5,10,11]. Several
further findings imply that lung CD4+ T cells might contribute to
COPD progression. Advanced COPD is associated with appear-
ance in the distal lung parenchyma of lymphoid follicles containing
germinal centers [5], which logically depend on T cell help. CD4+
T cells from emphysematous lungs showed reduced T cell receptor
(TCR) diversity implying oligoclonality and were more readily
expanded in vitro by IL-2, relative to those of never-smokers
without lung disease [12]. Expression of CD69, a cell-surface
receptor traditionally considered to be an early and transient
activation marker, by lung CD4+ T cells (and lung CD8+ T cells)
correlated both with spirometrically-defined COPD severity and
with the expression of co-stimulatory molecules on lung dendritic
cells (DC) from the same individuals [13]. Immunohistochemical
analysis demonstrated close contact between CD4+ T cells and
DC in the lung parenchyma [13]. Lung CD4+ T cells have been
implicated in organ-specific autoimmune lung destruction [14].
CD4+ T cells polarized to TH1 and TH17 phenotypes have been
identified in the lungs of emphysema patients, but not in lungs of
control subjects [15]. Collectively, these findings imply that lung
CD4+ T cells are acutely activated in advanced COPD, but their
precise function in pathogenesis remains controversial. Hence,
better understanding of the functional capacities of lung CD4+ T
cells is an important intermediate goal in development of novel
therapies to limit COPD progression.
In the current study, we used in vitro stimulation, flow
cytometry and real-time PCR to analyze human lung CD4+ T
cells from lung tissue resected for clinical indications. The results
were unexpected, based on the Tc1 effector-memory phenotype
that we previously found for lung CD8+ T cells (in many cases
from the same subjects as used in this study). Instead, despite a
decided predominance of the T effector-memory (TEM) pheno-
type, lung CD4+ T cells from many COPD subjects produced
CCL2 but virtually no IFN-c or other inflammatory cytokines
following TCR stimulation, relative to smokers with preserved
lung function. Hierarchical clustering analysis of unstimulated
RNA transcripts from isolated lung CD4+ T cells revealed that a
subset of subjects, mostly with COPD, were virtually devoid of
transcripts for TH1, TH2, TH17, and T regulatory (TReg)
transcription factors and cytokines, although they expressed some
upregulated transcripts that argued against global shutdown of
RNA synthesis. Further analysis identified associations of deficient
IL-10 with emphysema versus IFN-c with airflow obstruction
without emphysema. These cross-sectional data suggest that
independent impairments in the ability of lung CD4+ T cell to
produce specific cytokines might contribute to progression of
specific disease phenotypes in some susceptible smokers.
Methods and Materials
Ethics Statement
Studies and consent procedures were performed in accordance
with the Declaration of Helsinki at the VA Ann Arbor Healthcare
System and the University of Michigan Health System and were
approved by the Institutional Review Board at each site (FWA
00000348 and FWA 00004969, respectively). Written consent to
participate in the study was obtained preoperatively. The
institutional review boards have examined the protocols and
certified that ‘‘The risks are reasonable in relation to benefits to
subjects and the knowledge to be gained. The risks of the study
have been minimized to the extent possible.’’
Subject Enrollment & Patient Populations
Lung tissue was obtained from consented subjects undergoing
clinically-indicated resections for pulmonary nodules, lung volume
reduction surgery, or lung transplantation. All subjects (n=53)
underwent preoperative spirometry, collection of a variety of
clinical data including medications and history of recent (6 weeks)
respiratory infections, and clinical evaluation by a pulmonologist.
When available, non-contrast-enhanced CT scans (n=17) were
analyzed for percent emphysema using 3D Slicer software (www.
airwayinspector.org) and a threshold of ,2950 Hounsfield units.
Data on lung CD8+ T cells and lung dendritic cells on some
subjects in this study have been described previously [9,13].
We categorized subjects using the 2008 classification of the
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
[16]. Subjects (n=16) with a history of smoking .10 pack years, a
ratio of forced expiratory volume in 1 second to forced vital
capacity (FEV1/FVC) .0.70, normal spirometry, and no clinical
diagnosis of COPD represent smoking controls. Subjects (n=37)
with a smoking history .10 pack years, FEV1/FVC ,0.7 and
abnormal spirometry were considered to have COPD. Table S1
shows the number of subjects, sex ratio, age, smoking history,
spirometry, emphysema percent, and inhaled corticosteroid (ICS)
use for the entire cohort. Due to limitations in sample size and cell
yield, not all experiments could be performed on all subjects, and
conversely, some subjects were used in more than one type of
experiment.
Sample Preparation & Experimental Design
We collected only non-neoplastic lung tissue remote from any
nodules and lacking post-obstructive changes as determined by a
pathologist. Lung tissue (,3 g) was mechanically disaggregated
without enzymes, which we have previously shown yields a single
cell suspension of high viability and functional competence as
assayed in vitro [8,13,17]. Cells were filtered through a 40 mm
strainer to remove debris, then were used in one or more ways:
immediate processing for flow cytometry (n=22); or isolation of
CD4+ T cells. To isolate lung CD4+ T cells, unlabelled lung
homogenate was first passed through a Macs LS column (Miltenyi
Biotec, Auburn, CA) removing large cells, especially macrophages,
which remain stuck in the column. Next, human-specific CD4
microbeads and positive selection on second Macs LS columns
further enriched for CD4+ cells [9], which were used for real-time
PCR analysis of RNA (n=31) or in vitro experiments (n=29).
Flow Cytometric Analysis
Cells were stained as previously described [13]. We used
monoclonal antibodies against the following antigens (clones
shown in parentheses): CD45 (HI30), CD3 (HIT3a), CD4
(OKT4), CD8 (HIT8a), CD56 (N-CAM), CD27 (O323) and
CD62L (Dreg 56) (eBioscience, San Diego, CA). Antibodies and
isotype-matched controls were directly conjugated to either
fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoery-
thrin- cyanine 7 (PE-Cy7), allophycocyanin (APC), Pacific Blue,
Alexa Fluor 700, or biotin, with the biotinylated antibodies
developed using streptavidin-phycoerythrin-cyanine 5 (SA-PE-
Cy5). We assessed viability in all experiments using a Live/Dead
Fixable Near-IR Dead Cell Stain Kit for 633 nm excitation
(Invitrogen, Carlsbad, CA). Immediately after staining, cells were
Aberrant Lung CD4+ T Cells in COPD
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tubes were then stored at 4uC in a rack wrapped in aluminum foil
until analyzed.
Experiments were performed on an LSR II flow cytometer (BD
Bioscience, San Jose, CA), equipped with the following lasers:
488 nm blue, 405 nm violet laser, 633 nm red HeNe laser, and a
561 nm yellow-green laser. Data were collected using FACSDiva
software (BD Biosciences) with automatic compensation and were
analyzed using FlowJo software (Tree Star, Ashland, OR). We
collected at least 10,000 viable CD45+ events per sample in each
experiment.
CD4+ T Cell in vitro Stimulation
Isolated CD4+ T cells were cultured in 96-well plates at 50,000
cells per 200 ml in lymphocyte culture media (10% FBS, 1 mM
sodium pyruvate, 0.5 mM 2-Mercaptoethanol, 1 mM HEPES,
100 U/mL penicillin, 100 U/ml streptomycin, 0.292 mg/mL L-
Glutamine). Cells were stimulated with plate-bound anti-CD3e
(eBioscience) at a concentration of 5 mg/mL or with media alone.
After 48 hours, supernatants were collected and stored at 220uC
until analyzed. We determined IFN-c, TNF-a, IL-13, IL-17A, IL-
10, CCL2, CCL3, and CCL5 protein using multiplex bead sets
(Invitrogen) and a Luminex 200 system (Luminex Corporation,
Austin, TX), according to manufacturer’s instructions.
Quantitative Real-time PCR
Micoro Poly(A) Pure kits (Ambion, Austin, TX) were used to
isolate RNA from CD4+ T cells, and any contaminating genomic
DNA was removed using DNA-free kits (Ambion). Each RNA
sample was reverse-transcribed in a 20 ml reaction using Super-
Script II RNase H
2 Reverse Transcriptase (Invitrogen Corpora-
tion, Carlsbad, CA). We purchased TaqMan Universal PCR
master mix and all primer-probe sets from Applied Biosystems.
Transcripts were analyzed in duplicate (384-well format) on an
ABI PRISM 7900HT (Applied Biosystems) using the comparative
threshold cycle method, as described [9]. Delta Ct (DCt) was
calculated by subtracting the reference gene Ct from the target




dehydrogenase was used as the endogenous reference gene.
Analysis of Telomere Length by Real-time PCR
We assessed telomere length using a quantitative real-time PCR
assay originally described by Cawthon [18], which we performed
in duplicate using the same primers and conditions as described by
Savale and colleagues [19]. This method compares copy numbers
of the telomere repeat (T) to number of a single-copy gene (S) to
yield a T/S ratio. The assay was performed on DNA from purified
lung CD4+ T cells, which we isolated from the phenol phase and
interphase of samples homogenized in TRI reagent (Ambion)
following the manufacturer’s protocol. We determined concentra-
tions of both products by the comparative threshold cycle method
(T/S=2
2DDCt) using SYBR green (Invitrogen) and a Mx3000P
real-time PCR system (Stratagene). As the reference single-copy
gene, we used acidic ribosomal phosphoprotein PO (36B4).
Statistical Analyses
The majority of statistical analyses were performed using
GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA) on
a Macintosh Quad-Core Intel Xeon computer running OS 10.8.3
(Apple; Cupertino, CA). Mann-Whitney t tests were used to
compare two groups. We used nonparametric (Spearman)
correlation analysis to determine the correlation coefficient, rS.
Multiple linear regression was performed using SPSS Statistics
21.0 (IBM Corp.; Armonk, NY). The heat map and hierarchical
clustering analyses were generated using the open-software
program R 2.15.3 (http://www.r-project.org); Row Z scores were
calculated from log-transformed arbitrary units (arbitrary uni-
ts=2
2(target Ct – reference Ct) 610
3). A two-tailed p value of ,0.05
was considered to indicate significance.
Results
CD4+ T cells from Many COPD Subjects have Impaired
Production of IFN-c Following TCR Stimulation
To gain insight into the possible roles of lung CD4+ T cells in
COPD pathogenesis, we prospectively recruited subjects (n=53)
undergoing clinically-indicated lung resection procedures
(Table 1), comparing subjects with COPD versus smokers with
preserved spirometry. The groups differed significantly in smoking
history expressed as pack-years, in FEV1% predicted, emphysema
extent, indication for surgery and use of ICS, but not in age, sex or
smoking status expressed as active versus former smokers (defined
as having quit for more than 6 months). The emphysema extent
found in the smokers without COPD was only slightly greater than
that determined in healthy never-smokers at autopsy [20–22] or
by comparable CT scan measurements [23].
Using the freshly harvested lung tissue of both groups, we
performed a variety of experiments on CD4+ lung T cells. Due to
limitations in tissue size and cell yield, not all experiments were
performed on all individuals, and conversely, some subjects were
used in more than one type of experiment. For this reason,
characteristics of the subjects used in each type of experiment are
shown separately in Supporting Tables S1–S6. Some of these
subjects (n=28) were previously described in similar analyses of
lung DCs and lung CD8+ T cells [9,13,17].
First, to determine the functional ability of the lung CD4+ T
cells to produce cytokines and chemokines, we isolated viable
CD4+ T cells from the mechanically dispersed lung tissue of
smokers with normal pulmonary function (n=6) and COPD
subjects (n=23) (Table S1), using immunomagnetic beads. After
isolation, a median purity of 94% was obtained for the CD4+
fraction. Based on flow cytometry, these cells are predominantly
CD3+ (92.764.8%), suggesting that contamination with DCs or
macrophages was minimal. Representative histograms for CD4
staining are shown both before and after isolation (Figs. S1A,
S1B). These isolated CD4+ T cells were cultured without or with
in vitro stimulation by plate-bound anti-CD3e, and supernatants
were analyzed by Luminex assay. Unstimulated lung CD4+ T cells
made very little of any of the molecules measured and were
typically below the minimum detectable limit of 5 pg/ml. with no
relationship to lung function (data not shown).
Stimulated lung CD4+ T cells from COPD subjects displayed
significantly impaired IFN-c production compared to the smokers
with preserved pulmonary function (Fig. 1A). Conversely,
production of CCL2 was significantly augmented in the COPD
subjects, and CCL3 showed a trend towards increased production,
which did not attain statistical significance (Fig. 1B, 1C). The
significant differences in IFN-c and CCL2 between subjects with
COPD and smokers without COPD persisted after adjustment for
sex, age, ICS use and pack-years. Interestingly, for all three
analytes, a bimodal distribution can be noted in COPD subjects
(i.e., cells of some subjects produced protein whereas a substantial
fraction produced virtually none). There was no significant
relationship between the production of IFN-c and CCL2 or
CCL3 by individual subjects (not shown). Following TCR
stimulation, protein levels for the following analytes did not differ
Aberrant Lung CD4+ T Cells in COPD
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concentrations (mean 6 SD) were low in both groups: IL-10
(57690 vs. 50673 pg/mL); IL-13 (47694 vs. 28655 pg/mL); IL-
17A (undetectable; minimum detectable concentration=20 pg/
mL); TNF-a (13615 vs. 31653 pg/mL); CCL5 (4316511 vs.
5136673 pg/mL).
Thus, global stimulation of CD4+ lung T cells of most subjects
with COPD did not induce a TH1 cytokine profile, as that of the
same cell type in many smokers with normal spirometry.
Moreover, these results for lung CD4+ T cells were in marked
contrast to the production of IFN-c and TNF-a by lung CD8+
cells following the same TCR stimulation in subjects with COPD
[9]. In additional experiments comparing TCR-stimulated CD4+
T cells and CD8+ T cells from the same 6 subjects, we are able to
demonstrate a significant difference in the production of IFN-c
(886144 pg/mL by CD4+ T cells vs. 3776399 pg/mL by CD8+
T cells; p=0.03). Nevertheless, the lung CD4+ T cells of many
COPD subjects did abundantly produce CCL2 and CCL3,
indicating that they were not refractory to stimulation.
Reduced TEM Phenotype among Lung CD4+ T cells in
COPD
Next, to assess the phenotype of lung CD4+ T cells, we
performed flow cytometry on single-cell suspensions from whole
lung tissue (Table S2). We measured surface expression of
CD62L (a homing molecule also known as L-selectin) and CD27
(the receptor for the TNF family member CD70; down-regulated
following T cell activation) (Fig. 2A, 2B). Both these receptors are
low-to-absent on effector memory T cells (TEM), which we have
previously shown comprise the predominant subset among lung
CD8+ T cells in all spirometrically-defined stages of COPD [9].
We used additional surface markers to gate on isolated lung CD4+
T cells, which were defined as being viable cells positive for CD45,
CD3 and CD4, and negative for CD8 and CD56.
Compared to lung CD4+ T cells of smokers with preserved lung
function (n=7), those of subjects with COPD (n=15), showed a
significant decrease in the percentage of lung CD4+ T cells that
were double-negative for CD62L and CD27 (Fig. 2C), which
have conventionally been thought to be the active TEM phenotype
responsible for most cytokine secretion. Importantly, however, as it
was in all smokers with normal spirometry (Figure S2A),T EM
remained the most frequent phenotype in the majority of COPD
subjects (10 of 15) (Figure S2B).
The decrease in the proportion of TEM lung CD4+ T cells was
accompanied by a significant increased frequency of cells double-
positive for CD62L and CD27 (Fig. 2D). This heterogeneous
population could include both naı ¨ve T cells and central-memory T
cell (TCM), i.e., exactly the mixture that would be anticipated to be
found in organized lymphoid tissue, which is known to develop
within lung parenchyma as COPD progresses [5]. Because these
experiments did not include additional markers of memory
phenotype (e.g., CD45RA, CCR7 or CD44), it is not possible to
determine the percentage of naı ¨ve versus TCM cells in individual
subjects. Nevertheless, this double-positive fraction exceeded the
percentage of TEM cells among lung CD4+ T cells in only two of
the 15 COPD subjects. Hence, it appears unlikely that the failure
of lung CD4+ T cells to produce IFN-c in response to plate-bound
anti-CD3e in the COPD subjects (Fig. 1) resulted from a
predominance of naı ¨ve T cells. There was also a trend towards
an increase in cells that were positive for CD27 but negative for
CD62L (Fig. 2E), which did not attain statistical significance.
This phenotype is less well studied than TEM in both humans and
mice, but has been proposed to define recently activated CD4+ T
cells in transition to the full effector phenotype [24].
No differences were observed in the frequency of CD4+ T cells
as a percentage of leukocytes or of all lymphocytes when
comparing smokers with preserved lung function (defined
spirometrically) to COPD subjects (data not shown).
Stimulated IFN-c Production Correlates with the
Percentage of Lung CD4+ T cells Expressing CD103+
Until recently, TEM and TCM were the only defined memory T
cell populations. However, a third memory population, tissue-
resident memory T cell (TRM), has been identified in several tissues
in murine models, especially in the lungs following resolution of
viral respiratory infections [25,26], and also in the healthy human
lung [27]. We took advantage of the inclusion in these experiments
of antibody against CD103 (alpha E integrin), one of the defining
characteristics of this population. We found no difference between
smokers with normal spirometry and COPD subjects (Table S3)
in the fraction of cells expressing CD103 (Fig. 3A), which were a
minority of lung CD4+ T cells in both groups.
Table 1. Summary of demographics, smoking history, spirometry, emphysema, and inhaled steroid usage for entire cohort
1.
Group Smokers with normal spirometry COPD p value
Subjects, n 16 37
Sex ratio, M/F 11/5 25/12 0.99
Age, years (SD) 64 (11) 63 (10) 0.84
Smoking, pack-years (SD) 43 (43) 63 (36) 0.02
Smoking status (Active/Former
2) 9/7 23/14 0.76
FEV1, % predicted (SD) 97 (14) 46 (27) ,0.0001
FEV1/FVC (SD) 0.78 (0.05) 0.45 (0.19) ,0.0001
Emphysema, % (SD) 6 (11)
2 31 (14) 0.0006
Cancer as indication for surgery (yes/no) 16/0 18/19 0.0003
Lung transplant (yes/no) 0/16 11/26 0.02
ICS use (yes/no) 1/15 21/16 0.0006
1Data are presented as average (SD) except for sex ratios, smoking status, indication for surgery, and ICS use; M, male; F, female; ICS, inhaled corticosteroids;
2former smoker defined as having quit for more than six months.
doi:10.1371/journal.pone.0096421.t001
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and flow data from both smokers and COPD subjects (total n=15)
(Table S3), there was a significant correlation (rS=0.55,
p=0.025) between the percentage of CD103+ cells and stimulated
production of IFN-c in vitro by the lung CD4+ T cells of the same
individuals (Fig. 3B). IFN-c production did not correlate with the
percentage of TEM cells, CD62L+ CD27+ double-positive cells, or
CD27+ CD62L2 single-positive cells in this group.
COPD Subjects and Smokers with Preserved Lung
Function Largely Segregate into Two Distinct Groups
based on Basal RNA Transcripts
Next, we used real-time RT-PCR to analyze mRNA transcripts
of 27 selected genes from isolated, unstimulated lung CD4+ T cells
from smokers with preserved pulmonary function (n=8) or COPD
subjects (n=23) (Table S4). Candidate genes were chosen to
include the transcription factors and target genes characteristic of
the major polarized CD4+ T cells subsets; we also analyzed
selected chemokines, regulatory receptors and genes associated
with T cell anergy, in an attempt to understand the molecule basis
of our earlier results. Data were log-transformed for heat map
analysis. Interestingly, as illustrated by the dendrogram (Fig. 4),
unsupervised hierarchical clustering separated the entire group of
subjects into two distinct groups. The group on the left (Group A)
consisted of 14 of the 23 COPD subjects and two of the eight
smokers with preserved lung function, while the group on the right
(Group B) contained the remaining nine COPD subjects plus six
smokers (Fig. 4). The division into two groups appeared to be
driven by broad down-regulation, indicated by red to pink
shading, of multiple polarizing transcription factors and their
target genes in Group A subjects, which contrasted with the
predominately upregulated expression (relative to reference genes,
blue shading) of the same genes in Group B subjects.
We next investigated whether the separation of subjects into
Group A or Group B based on lung CD4+ T cell mRNA
expression correlated with pulmonary function. Despite consider-
able overlap, we found that subjects in Group A had a significantly
decreased FEV1% predicted, as well as a lower FEV1/FVC ratio
that just failed to attain significance, relative to all subjects in
Group B (Fig. 5A, 5B). However, there was no difference in
DLCO % predicted (Fig. 5C). We also found no difference
between these transcript-defined groups when we analyzed age,
sex, pack years, current smoking status, BMI, inhaled corticoste-
roid usage, or presence of malignancy or transplant as the
indication for surgery (Table 2).
Because hierarchical clustering examines levels of all 27
transcripts simultaneously, to determine which individual tran-
scripts were actually significantly different between the two groups,
we extended these analyses by performing Mann-Whitney t-tests
while maintaining the Group A and Group B designations
assigned by the dendrogram. Significant decreases were seen in
the Group A subjects for the transcription factors for TH1, TH2,
TH17, and TReg subsets, T-bet (Fig. 6A), GATA-3 (Fig. 6B),
ROR-c (Fig. 6C) and FOXP3 (Fig. 6D), respectively, all of
which were barely detectable in most Group A subjects.
Transcripts for the TH1 signature gene IFN-c (Fig. 6E) and for
the TH17 cytokines IL-17A and IL-22 (6G, 6H) were also
significantly reduced in Group A individuals, compared to Group
B. The Th2 cytokine, IL-5, (Fig. 6F) showed no significant
difference and transcripts were close to undetectable. IL-4 and IL-
13 transcripts were undetectable, therefore they were not included
in either the heat map or the individual analyses. Thus, in contrast
to the balanced expression of transcription factors and genes for
multiple polarized CD4+ T cell subsets in the Group B subjects,
we found significantly decreased expression of all T cell subsets in
Group A.
Importantly, however, we found elevated expression in lung
CD4+ T cells from Group A subjects for two of the candidate
genes. These were the chemokine CCL2 (Fig. 6I), in agreement
Figure 1. TCR-stimulated lung CD4+ T cells produce less IFN-c
protein but more CCL2 in COPD. Isolated lung CD4+ T cells were
stimulated with plate-bound anti-CD3e for 48 hours. Supernatants were
collected and Luminex assays were used to measure (A) IFN-c, (B) CCL2,
and (C) CCL3 for smokers with normal spirometry (orange diamonds;
n=6) and COPD subjects (blue diamonds; n=23 for panel A; n=18 for
panels B & C). Each symbol represents an individual patient; solid lines
represent the mean 6 SEM. The dashed line represents the minimum
detectable concentration. The Mann Whitney t-test was used to
determine significant differences between groups.
doi:10.1371/journal.pone.0096421.g001
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as a whole (Fig. 2), and CCAAT-enhancer-binding protein
homologous protein (CHOP) (Fig. 6J). Thus, the virtually absent
expression of mRNA transcripts for IFN-c and multiple
transcription factors seen in the Group A subjects does not reflect
a global inability to elaborate any RNA transcripts.
Examination of Possible causes for Reduced Polarization
and Cytokine Transcripts in Group A Subjects
We analyzed other genes specifically to test several potential
explanations for widespread gene down-regulation in Group A
subjects. Significant reductions were seen in Group A in
transcripts for three negative-regulatory members of the CD28
superfamily, CTLA-4, ICOS (Fig. 6K, 6L) and BTLA (Fig.
Figure 2. The TEM subset of lung CD4+ T cells is significantly decreased in COPD patients. Single cell suspensions of mechanically
disaggregated human lung tissue were stained and analyzed by flow cytometry. A, B. Representative flow plots showing staining for CD62L
(horizontal axis) versus CD27 (vertical axis) on gated CD4+ T cells from (A) a smoker normal spirometry and (B) a subject with COPD. Small blue
numbers are the percentage of CD4+ T cells in each quadrant. C–E. Aggregated percentages of lung CD4+ T cells from smokers with normal
spirometry (orange; n=7) and COPD subjects (blue; n=15) that were (C) negative for both CD62L & CD27 (TEM), (D) positive for both CD62L & CD27,
or (E) negative for CD62L but positive for CD27. Box-&-whisker plots indicating the first & third quartiles (box), median (band) and range (whiskers).
The Mann Whitney t-test was used to determine significance.
doi:10.1371/journal.pone.0096421.g002
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significant differences in the E3 ubiquitin ligases ITCH and Cbl-b,
which are reported to play a critical role in induction of T cell
anergy (Fig. S3B, S3C) [28,29]. No other significant differences
were seen among the genes tested in Figure 4, which included the
inhibitory molecule CD200R, CD38, cyclins D1 & E1, TIM3 or
RasGRF1 & 2 (not shown).
Next, to test for senescence in lung CD4+ T cells of Group A
individuals, we measured telomere length by a PCR-based method
used recently to demonstrate that the peripheral blood leukocytes
of COPD patients show reduced telomere length [4]. We found no
significant differences between groups in the telomere repeat copy
number to single-gene copy number (T/S) ratio (Fig. S3D),
implying that the difference is not explained by global senescence
of lung CD4+ T cells.
As mRNA yields permitted, we also measured expression by the
isolated lung CD4+ T cells of additional genes in some subjects
from these two groups (group A, n=7, all with COPD; Group B,
n=9, 4 COPD, 5 smokers without COPD) (Table S5). Although
limited by the smaller sample size, for all genes in which there was
a significant difference (Table S6), expression was higher in
Group B subjects, supporting the conclusions for the larger sample
sizes in Figure 6. Importantly, Group A subjects showed significant
reductions in three negative regulators of T cell function: Egr-2
and Egr-3 (which are upregulated by anergic T cells [30]).
Together with the data in Figure 3 and Figures S3B & S3C, these
results argue against anergy as a cause for the lack of polarization
of lung CD4+ T cell in Group A subjects.
IL-10 Transcripts Inversely Correlate with Emphysema
Scores in Group A vs. Group B Subjects
We asked whether the impaired transcript expression of the
lung CD4+ T cells in the Group A subjects might be associated
with lung CD4+ T cell expression of IL-10, a potent immuno-
modulator capable of suppressing inflammatory cytokines in
multiple cell types. We found no significant differences between
the two groups in levels of IL-10 transcripts (Fig. 7A), or in IL-10
protein levels following stimulation of lung CD4+ T cells with
plate-bound anti-CD3e (data not shown). However, among the
Group A and Group B subjects for whom analyzable (non-
contrast) CT scans were available (n=17), IL-10 transcripts did
show a significant inverse correlation with emphysema score, as
determined by non-parametric Spearman correlation (rS=20.54;
p=0.026) (Fig. 7B). The direction and magnitude of this
correlation was not changed after adjustment for ICS use, age,
sex, or pack-years. No correlations of IFN-c transcripts were seen
with IL-10 or emphysema score.
Group A Subjects have a Significant Reduction in the
Frequency of CD62L2, CD27+ lung CD4+ T cells
Next, we used the flow cytometry data available on the Group A
and Group B subjects to ask whether the marked disparity in lung
CD4+ T cell polarization and expression of mRNA for multiple
cytokine and chemokines correlated with expansion of TCM cells
or another well-defined T cell phenotype. Increased percentages of
CD4+ TCM and possibly of naı ¨ve CD4+ T cells in the lungs might
be anticipated to accompany expansion of organized peribronchial
lymphoid tissue, as has been shown to occur in more advanced
COPD [5]. This was, in fact, what we found on analyzing subjects
simply based on diagnosis of COPD (Fig. 2D). The data for this
final analysis are a subset of those presented in Figure 1; however,
because flow cytometry was necessarily performed within hours of
tissue harvesting, we were not aware of which subjects comprised
groups A & B until much later.
There were no significant differences between Group A and
Group B in the percentage of lung CD4+ T cells expressing either
TEM or CD62L, CD27 double-positive phenotypes (Figs. 8A,
8B). Unexpectedly, there was a significant decrease in Group A
subjects in the fraction of cells single-positive for CD27 (Fig. 8C).
Thus, we cannot readily relate the mRNA-defined Group A
classification to a CD4+ T cell surface phenotype, although this
analysis is obviously limited by the small number of subjects whose
cells underwent both flow cytometric and quantitative real-time
PCR analyses.
Impaired Pulmonary Function can be Predicted by IFN-c
Transcript Levels
Finally, we returned to the entire group of COPD subjects and
smokers without COPD on whom we had mRNA data (n=31) to
test for correlations of specific mRNA transcripts and FEV1%
predicted. Spearman non-parametric analysis found highly signif-
icant positive correlations with several analytes, including IFN-c
(r=0.57, p=0.0009), GATA-3 (r=0.51, p=0.004), CTLA-4
(r=0.48; p=0.006), FOXP3 (r=0.37, p=0.04), and an inverse
correlation with CCL2 (r=20.62, p=0.0003) (data not shown).
To determine which of these variables were able to predict
FEV1% predicted independently, we performed multiple linear
Figure 3. Production of IFN-c protein by stimulated lung CD4+
T cells correlates with CD103+ expression. Isolated lung CD4+ T
cells were stimulated with plate-bound anti-CD3e for 48 hours.
Supernatants were collected and Luminex assays were used to measure
IFN-c. A. Aggregated percentages of CD103+ cells among lung CD4+ T
cells of smokers with normal spirometry (maize; n=7) and COPD
subjects (blue; n=17). The Mann Whitney t-test was used to determine
significant differences between groups. B. Correlation between
stimulated IFN-c protein concentrations (vertical axis, log scale) and
percentage of CD103+ lung CD4+ T cells (horizontal axis). Smokers with
normal spirometry (orange diamond; n=3) and COPD subjects (blue
diamonds; n=14) are a subset of those in panel A, as not all subjects
had corresponding protein data. Statistics by Spearman correlation.
doi:10.1371/journal.pone.0096421.g003
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Transcripts for 27 genes were measured by real-time RT-PCR from isolated lung CD4+ T cells and results were displayed as a heat map. Columns
represent individual subjects; gene identities are shown on the right. Red=down-regulated, white=unchanged, blue=up-regulated, grey=missing
data. Based on spirometry plus clinical diagnosis, subjects were classified (top) either as smokers without COPD (green; n=8) or COPD (purple; n=23).
Unsupervised hierarchical clustering divided the subjects into two distinct groups, as indicated by the dendrogram. Group A contained 14 of 23
COPD subjects and two of eight smokers without COPD, while Group B consisted of the remaining six smokers without COPD and the other nine
COPD subjects. The Row Z scores were calculated from log-transformed arbitrary units.
doi:10.1371/journal.pone.0096421.g004
Table 2. Comparison of clinical characteristics of Group A & Group B subjects
1.
Group ABp value
Subjects, n 16 15
Sex ratio, M/F 8/8 11/4 0.27
Age, years (SD) 63 (8) 63 (11) 0.96
Smoking, pack-years (SD) 57 (20) 57 (53) 0.59
Smoking status (Active/Former
2) 9/7 10/5 0.72
FEV1, % predicted (SD) 50 (31) 73 (31) 0.039
FEV1/FVC (SD) 0.49 (0.20) 0.61 (0.20) 0.05
Emphysema, % (SD) 23 (15) 24 (19) 0.98
Cancer as indication for surgery (yes/no) 9/7 11/4 0.46
Lung transplant (yes/no) 2/14 2/13 0.99
ICS
3 use (yes/no) 9/7 6/9 0.48
1Data are presented as average (SD) except for sex ratios, smoking status, indication for surgery and ICS use; M, male; F, female;
2former smoker defined as having quit for more than six months;
3ICS, inhaled corticosteroids. The Mann Whitney t-test was used to determine significant differences between groups.
doi:10.1371/journal.pone.0096421.t002
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history, ICS usage, BMI and DLCO % predicted, a higher FEV1%
predicted was associated with higher levels of IFN-c transcripts
(p=0.04) (Table 3). Higher FEV1% predicted was also strongly
associated with higher DLCO % predicted (p=0.01). This
statistical model implies that, unlike the strongly positive
association we have previously described between advanced
COPD stage and spontaneous [8] or stimulated [9] production
of IFN-c by lung CD8+ T cells, waning production of IFN-c by
lung CD4+ T cells is significantly associated with spirometrically-
defined COPD progression.
Discussion
Using multiple analytic techniques on viable lung CD4+ T cells
isolated from 53 human subjects, this study disclosed five novel
findings in COPD, relative to smokers with normal spirometry.
First, following TCR stimulation, lung CD4+ T cells of most
COPD subjects produced virtually no IFN-c or other inflamma-
tory cytokines, but many produced relatively more chemokines
that could attract monocytes. Second, the surface phenotype of
lung CD4+ T cells in COPD was less uniformly TEM predom-
inant. Third, basal gene expression in our entire group identified a
phenotype, mainly in COPD subjects, characterized by markedly
reduced mRNA for the transcription factors necessary to polarize
multiple CD4+ T cell subsets (TH1, TH2, TH17 and FOXP3+
TReg) and for their signature cytokines. This finding did not result
from global inability to elaborate mRNA; greater expression of
transcripts for inhibitory CD28 family members or for markers of
anergy; or senescence (as indicted by reduced telomerase length).
Subjects with this novel mRNA-defined phenotype (Group A) had
significantly lower FEV1% predicted and non-significantly
reduced FEV1/FVC ratios, but not DLCO, relative to subjects
whose lung CD4+ T cells expressed a variety of transcripts.
Fourth, considering both COPD and smoking subjects, transcripts
for IL-10 correlated inversely with radiographically-defined
emphysema extent, but not with spirometry. Fifth, multiple linear
regression modeling identified expression of IFN-c mRNA by
unstimulated lung CD4+ T cells as an independent predictor of
FEV1% predicted, suggesting that loss of TH1 polarization may
contribute to, rather than result from, spirometrically-defined
COPD progression. These findings provide new insights into how
loss of appropriate immune functions mediated by lung CD4+ T
cells might contribute to COPD pathogenesis in susceptible
individuals.
Defending the lungs against diverse pathogens while minimizing
lung inflammation requires multiple CD4+ T cell subsets. These
subsets can be defined either by their polarized production of
specific cytokines (e.g., TH1, TH2, etc.) or in an independent
fashion, by their expression of cell surface receptors. We will first
consider the implications of our findings for each of these two T
cell definition schemes, before discussing their relationship to
anticipated results from published data on lung CD8+ T cells, and
our study’s limitations.
Heterogeneity of Cytokine-defined Subsets of Lung T
cells in COPD
Measurement of basal mRNA transcripts provide a snapshot of
a given cell type’s activity at the time of collection. We found that
basal levels of mRNA transcripts for IL-10 and IFN-c in lung
CD4+ T cells were unrelated in individual subjects, and were
inversely correlated with emphysema extent vs. spirometry,
respectively. These data did not depend on vitro experimental
manipulation, and derived from regression analysis of all subjects
with available data, making them the least subject to concerns
about categorization by diagnosis. By providing novel molecular
insights into the known clinical heterogeneity of this complex
syndrome, we consider the correlation of specific basal cytokine
Figure 5. Group A subjects are characterized by worse
spirometry than Group B subjects. Pulmonary function was
assessed for all subjects and is presented based on the groups defined
in Figure 4. (A) FEV1% predicted, (B) FEV1/FVC ratio, and (C) DLCO %
predicted are shown for Group A subjects (Xs; n=16) and Group B
subjects (circles; n=15). Orange symbols represent smokers without
COPD (n=8) and blue symbols represent subjects with COPD (n=23).
Symbols represent individual patients, lines represent the mean 6 SEM.
The Mann Whitney t-test was used to determine significant differences
between groups. N.S., not significant.
doi:10.1371/journal.pone.0096421.g005
Aberrant Lung CD4+ T Cells in COPD
PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e96421transcripts in lung CD4+ T cells with distinct clinical phenotypes
the most noteworthy of our current findings.
Based on our collective cytokine data, we propose that two
largely independent types of lung CD4+ T cell dysfunction
develop in some susceptible smokers and contribute to develop-
ment of individually variable in COPD phenotypes: (1) deficient
CD4+ T cell elaboration of IL-10, which fails to check auto-
aggressive activities of lung CD8 and NK cells leading to
emphysema; and (2) pervasive loss of CD4+ T cell polarization,
which leads to non-emphysematous pathologies that cause airflow
obstruction. The ultimate molecular bases for these dysfunctional
lung CD4+ T cell phenotypes remain uncertain. Some recent
evidence supports a systemic defect of CD4+ T cell polarization in
COPD [31], but we currently favor a specific effect of the lung
environment uniquely affecting lung CD4+ T cells for the loss of
polarization (Group A) phenotype.
These contrasting associations between IL-10 and IFN-c
provide a clear example of the importance of strictly defining
specific COPD phenotypes [32] for mechanistic studies. Although
generally considered part of the overall COPD syndrome,
increasing evidence implies that emphysema may result from
pathogenic mechanisms distinct from those fostering airways
disease. As recently stated by Manichaikul and colleagues
‘‘Emphysema on computed tomography (CT) is only moderately
correlated with lung function, is absent in some patients with
COPD, and occurs in the absence of COPD’’ [33]. The inverse
association between IL-10 transcripts and emphysema extent we
found is particularly significant given the independent role of
emphysema in mortality [34].
IL-10 is a potently anti-inflammatory cytokine that can
modulate many inflammatory and parenchymal cell types. Our
IL-10 results support and extend a previous analysis of whole lung
tissue [14], but contradict analysis of CD4+ T cells in broncho-
alveolar lavage [35], which may indicate anatomic compartmen-
talization of the pulmonary immune response. A potential strength
of our approach is that it derives from distal lung parenchyma, the
chief site of pathology in COPD [36]. Although IL-10 can either
stimulate or inhibit CD8+ T cells depending on the context [37],
IL-10 does act on antigen-presenting cells to prevent their
maturation and to decrease stimulatory molecule expression
[38]. Hence, deficient Il-10 production by lung CD4+ T cells
might indirectly permit greater activation of auto-aggressive CD8+
lung T cells. IL-10 polymorphisms have been associated with
airflow obstruction (but not emphysema) in some [39,40] but not
all studies [41], suggesting a possible genetic basis.
Why basal IFN-c transcripts in lung CD4+ cells significantly
and independently correlate with abnormal spirometry is not
immediately apparent, especially given the strong evidence that
Figure 6. Group A subjects have significantly reduced transcripts for multiple polarizing transcription factors & signature
cytokines. Lung CD4+ T cells were isolated for RNA analysis by real-time RT-PCR and mRNA transcripts are displayed as arbitrary units according to
the subject groups defined by the heat map analysis in Figure 4. Group A (Xs; n=16) and Group B (circles; n=15). (A) T-bet, (B) GATA-3, (C) ROR-c, (D),
FOXP3, (E) IFN-c, (F) IL-5, (G) IL-17A, (H) IL-22, (I) CCL2, (J) CHOP, (K) CTLA-4 and (L) ICOS. In both groups, orange symbols represent smokers without
COPD (n=8) and blue symbols represent subjects with COPD (n=23). Symbols represent individual patients, lines represent the mean 6 SEM. The
Mann Whitney t-test was used to determine significant differences between groups. N.S., not significant.
doi:10.1371/journal.pone.0096421.g006
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the possibility that IFN-c is serving as a surrogate for some factor(s)
not measured in our study but also defective in the Group A
subjects. Although excessive CCL2 production could fuel recruit-
ment to the lungs of monocytes that could specifically drive
inflammation, CCL2 was not an independent predictor of
spirometric outcomes in our logistic model.
Our finding that lung CD4+ T cells from most smokers with
normal spirometry produced a variety of cytokines on stimulation
agrees with a study of normal human lung tissue [27], despite
difference in methods of isolation and stimulation. By studying
both emphysematous and non-emphysematous lungs, our results
complement and are not necessarily at odds with a study of lung
CD4+ T cells from emphysematous subjects, which detected
stimulated IFN-c and IL-17A production using sensitive intracel-
lular flow cytometric staining [15]. Because both those investiga-
tors and we examined relatively small groups of subjects, it is
possible that our two laboratories have identified separate
prototypic molecular subtypes within the broad spectrum of
COPD phenotypes. Alternatively, an intriguing possibility that
would reconcile results of our two studies would be an in vivo
block in signaling just distal to the TCR, detectable by our
approach but not by PMA/ionomycin stimulation, which activates
downstream of TCR.
Figure 7. Decreased IL-10 mRNA transcripts in lung CD4+ T
cells correlate with worsening emphysema. Lung CD4+ T cells
were isolated for analysis of IL-10 mRNA by real-time RT-PCR. (A) mRNA
transcripts presented in the Group A and Group B subject groups
defined in Figure 4. Symbols, which represent individual subjects, are as
described in the Legend to Figure 6; lines represent the mean 6 SEM.
The Mann Whitney t-test was used to determine significant differences
between groups; N.S., not significant. (B) Relationship of IL-10 mRNA
transcripts in lung CD4+ T cells, expressed as arbitrary units (vertical
axis), to percent emphysema (2950 HU threshold) (horizontal axis)
(n=17). Spearman non-parametric analysis was used to calculate rS and
p values.
doi:10.1371/journal.pone.0096421.g007 Figure 8. Group A subjects have expansion of an unusual
population (CD62L2, CD27+), but not of TEM. Available flow
cytometry data on subjects in Group A and Group B were analyzed to
determine the fraction of lung CD4+ T cells in each of the quadrants
defined by CD62L and CD27 expression. (A) CD62L2 CD272 TEM; (B)
CD62L+ CD27+; (C) CD62L2 CD27+. Symbols represent individual
patients, lines represent the mean 6 SEM. Group A subjects (Xs; n=8)
and Group B subjects (circles; n=6); orange symbols represent smokers
without COPD (n=3) and blue symbols represent subjects with COPD
(n=10). The Mann Whitney t-test was used to determine significant
differences between groups. N.S., not significant.
doi:10.1371/journal.pone.0096421.g008
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of many COPD subjects, which aligns with several studies on lung
TReg cells in COPD [14,27,42], is significant given the conflicting
data on this subset. Our conclusions disagree with two studies
[43,44] that relied on CD25 expression, a less specific indicator of
TReg cells. Because those studies also analyzed bronchoalveolar
lavage fluid, disparity from our data might also reflect the
difference in anatomic compartmentalization. Differences in
methodology complicate direct comparison with the results of a
study that used immunohistology to determine that CD4+
FOXP3+ cells were increased in the follicles from COPD patients
compared to smokers and non-smokers [45]. Once again, the
range of this measurement in our individual COPD subjects
argues that a deficiency in inducible TReg may not be uniform in
this heterogeneous disease. Considerably larger numbers of
COPD subjects must be analyzed before this or any deficit can
be accepted as a universal feature of COPD pathogenesis.
Cell Surface Receptor-defined Subsets of Lung T cells in
COPD
Independently of polarized cytokine production, T cell subsets
can also be categorized using surface receptors that correlate with
activation history, trafficking and memory status. For over a
decade [46], surface receptor-defined T cell categories have
consisted of naı ¨ve cells, short-lived TEM cells and persistent TCM
subsets. These three categories have been demonstrated most
convincingly in CD8+ T cells. In this study, we identified TEM
using low expression of CD62L and CD27, a valid indicator for
both CD8+ and CD4+ human subsets. Our identification of the
TEM subset as the majority of lung CD4+ T cells in smokers
without COPD also agrees with results from normal human lung
tissue [27], although we identified TEM using different, but equally
well-established receptors. That lung CD4+ T cells are predom-
inately TEM in COPD agrees with an earlier study [12]. Because
TEM have a lower activation threshold than naı ¨ve or TCM cells,
our flow cytometric data do not explain the reduced IFN-c protein
production by many of our COPD subjects. Our data also suggest
that Group A subjects may be relatively deficient in T follicular
helper cells, which strongly express ICOS and CXCR5, the
receptor that guides homing of CD4+ T cells to germinal centers
[47,48]. Because CD4+ regulation is essential to prevent
autoimmunity during immunoglobulin class-switching, our find-
ings may partially explain detection of auto-antibodies in
advanced COPD [14,49], especially given the observation that
CD40L appears reduced in Group A subjects (p=0.055, Table
S4).
Further, we provide novel insight on the recently described T
resident-memory (TRM) subset [50]. Our data extend previous
finding of a human lung TRM population in normal subjects, by
showing that the percentage CD4+ T cells expressing CD103, a
marker of intraepithelial localization, correlates directly with basal
transcripts for IFN-c among both smokers and COPD subjects.
Based on results in murine models, the CD4+ TRM cells in the
lungs of both smokers and COPD subjects likely result from
previous viral respiratory infections [50].
However, assigning tissue-resident T cells to receptor-defined
categories has recently become more difficult for human CD4+ T
cells. Several receptors that reliably subdivide CD8+ T cells,
including CD28 (which we measured) and CCR7 (which we did
not), are now known to be expressed by both naı ¨ve and TCM
human CD4+ cells [50,51]. Hence, because our flow cytometry
experiments were originally designed to analyze CD8+ lung T cells
in the same samples by eight-color analysis and did not include
determination of CD45 isoforms, we cannot distinguish the naı ¨ve
and TCM CD4 subsets in the current data. It is intriguing that
COPD subjects had increased percentages of a different subset of
lung CD4+ cells, CD62L2, CD27+ cells, which in a murine
model of pulmonary tuberculosis have been linked to defective
IFN-c production [52].
Because TEM still predominated in most COPD subjects, we
doubt that the relatively small changes in the various non-TEM
phenotypes in COPD subjects adequately explain impaired
stimulated IFN-c protein responses. None of the lung CD4+ T
cell subsets defined by CD62L and CD27 correlated with IFN-c
protein (not shown). Nor could surface phenotypic differences
explain the absence of lung CD4+ cell polarization in Group A
subjects, in whom the CD62L2, CD27+ subset was relatively
reduced and other subsets unchanged. Thus, flow cytometry
cannot at present be used to identify smokers lacking robust lung
CD4+ T cell polarization.
Relationship of Current Findings to Lung CD8+ T cells in
COPD
Results for both stimulated cytokine production (both mRNA
and protein) and for basal gene expression were contrary to
expectations from several previous studies of lung T cells,
including our own [5,13,35,53]. Those studies established that as
spirometry worsens, lung CD8+ T cells develop a strictly Tc1
Table 3. Linear regression model to evaluate ability of variables to predict FEV1% predicted.
Variable B
1 Std. error
1 Sig. 95% CI Lower bound, Upper bound
Dependent variable=FEV1 (% predicted)
Independent variables:
Age 0.74 0.46 0.13 20.23, 1.7
Sex 22.7 9.3 0.78 222.3, 16.9
Smoking, pack-years 20.07 0.13 0.58 20.34, 0.19
DLCO, % predicted 0.61 0.22 0.01 0.14, 1.1
Current smoking status 2.72 9.66 0.78 217.6, 23.0
ICS 220.3 11.7 0.10 244.8, 4.3
BMI 21.16 0.91 0.22 23.1, 0.74
IFN-c 0.03 0.02 0.04 0.00, 0.06
1Unstandardized Coefficients. Sig., significance; CI, confidence interval.
doi:10.1371/journal.pone.0096421.t003
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numbers and apparent activation states of both lung CD8+ and
CD4+ T cells increase in parallel. However, the current
experiments used identical isolation techniques and in over half
of cases the same lung specimens as our previous studies of other
lung leukocyte types [8,9,13,17]. Hence, we believe that artifact
related to our method of T cell isolation is highly unlikely.
Additionally, in paired experiments isolating lung T cells from the
six subjects, we showed that lung CD8+ T cells make significantly
more IFN-c following TCR stimulation than lung CD4+ T cells.
There are several ways in which the current findings and
published data on CD8+ T cells in COPD can be reconciled with
the known dependence for optimal induction of CD8+ cytolytic
responses on CD4+ T cell help, mediated largely via cytokines.
First, CD8+ T cells might still receive adequate help in regional
lymph nodes if defective production of inflammatory cytokines by
CD4+ T cells in COPD were limited to the lungs, but that
possibility has recently been questioned [31]. Additionally, CD4-
independent CD8+ T cells responses have been observed in
tumors and several infectious diseases [54]. NK cells can induce
primary CD8+ T cell immunity against intracellular infections
[55] in the absence of CD4+ T cells. Proliferation and
differentiation of antigen-specific CD8+ T cells can also be
stimulated directly by Type I IFNs [56], which multiple cell types
can elaborate. CD8+ T cells are also typically subjected to
negative control by FOXP3+ TReg cells [57], which our data
suggest are reduced in many COPD subjects with the Group A
phenotype.
Limitations
This study has several limitations. Arguably the greatest is that
not all studies could be performed on samples from all subjects,
restricting the sizes of groups in which multiple variables could be
compared. Hence, we welcome examination of the veracity of our
conclusions in larger groups of subjects. Another is its dependence
on tissue removed for clinical indications, raising possible
questions of generalizability. Because our subjects were candidates
for surgery, they likely have fewer co-morbidities and superior
performance status for spirometrically-defined stage, relative to all
COPD patients of similar age. Hence, it is unlikely that debility
explains our findings. None of our subjects had suffered a
respiratory infection within six weeks of surgery, and we strictly
avoided any areas suspicious for possible post-obstructive pneu-
monia. Importantly, we found no correlations of our findings with
malignancy as the indication for surgery or with use of ICS.
Although 11 of our samples were explants harvested at the time of
lung transplantation, recipients in our program do not receive pre-
or intraoperative immunosuppression prior to lung removal.
Additionally, we do not present data on co-stimulation of lung
CD4+ T cells via CD28 or CD2 in addition to CD3, and
therefore, do not claim that these cells are utterly refractory to
optimal stimulation. Future studies will be needed to explore that
point and to determine the ultimate molecular basis for our
findings.
Conclusion
In summary, we demonstrate that despite evidence of an
activated phenotype, lung CD4+ T cells in many subjects with
COPD are not polarized to any conventional subset and do not
readily produce inflammatory cytokines when polyclonally stim-
ulated. We identified significant independent correlations of levels
of unstimulated mRNA transcripts in lung CD4+ T cells with
specific COPD phenotypes: reduced IL-10 transcripts were
associated with emphysema, whereas pervasive absence of T-cell
polarization was associated with airflow obstruction. By delineat-
ing the sharp contrast with the behavior of other lung leukocyte
subtypes in advanced disease, our data highlight the value of
analyzing isolated cell types to disclose findings not evident from
global analyses of gene expression. These findings imply that, at
least in some subjects, advanced COPD may be a state of
simultaneous local immune deficiency and dysregulation, a novel
paradigm for this leading worldwide cause of death and disability.
Supporting Information
Figure S1 Representative staining for CD4 on isolated
lung T cells. A, B. Representative histograms showing staining
for CD4 lung T cells before (A) and after (B) isolation by immuno-
magnetic beads.
(TIF)
Figure S2 Memory phenotypes of lung CD4+ T cells in
individual subjects. A, B. Percentages of lung CD4+ T cells in
the four possible quadrants defined by analysis of CD62L &
CD27. Data are stacked columns for each subject (numbers on
horizontal axis); double-negative cells (TEM) are colored violet and
located on the bottom, followed in ascending order by cells that
are single positive for CD27 (neon green), double-positive (TCM
and naive) (scarlet), and single-positive for CD62L (mustard-
colored).
(TIF)
Figure S3 The Group A phenotype is not characterized
by genes associated with anergy, negative co-stimulation
or by senescence. Lung CD4+ T cells were isolated either for
(A–C) RNA analysis by real-time RT-PCR or (D) to harvest DNA
for analysis of the ratio of numbers of telomere repeats (T) to
number of a known single copy gene, using the comparative
threshold cycle method of PCR analysis [19]. (A) BTLA, (B)
ITCH, (C) Cbl-b are shown for Group A subjects (Xs; n=16) and
Group B subjects (circles; n=15). Orange symbols represent
smokers without COPD (n=8) and blue symbols represent
subjects with COPD (n=23). Symbols represent individual
patients, lines represent the mean 6 SEM. The Mann Whitney
t-test was used to determine significant differences between groups.
N.S., not significant.
(TIF)
Table S1 Summary of demographics, smoking history,
spirometry, indication for surgery and ICS usage for
subjects used in stimulated protein experiments.
(DOCX)
Table S2 Summary of clinical characteristics of sub-
jects used in flow cytometry experiments.
(DOCX)
Table S3 Summary of clinical characteristics of sub-
jects used in CD103 versus IFN-c correlation experi-
ments.
(DOCX)
Table S4 Summary of clinical characteristics of sub-
jects used in mRNA heat map analysis.
(DOCX)
Table S5 Summary of clinical characteristics of sub-
jects used to measure additional mRNA transcripts.
(DOCX)
Table S6 Human lung CD4 transcripts in Group A
versus Group B subjects.
(DOCX)
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